Baryshnikova Ekaterina, Ranucci Marco
Department of Cardiothoracic and Vascular Anesthesia and Intensive Care, IRCCS Policlinico San Donato, Via Morandi 30, 20097 San Donato Milanese, Milan, Italy.
Eur Heart J Suppl. 2016 Apr 28;18(Suppl E):E42-E48. doi: 10.1093/eurheartj/suw013. Epub 2016 Apr 29.
A rational management of perioperative and postoperative bleeding in modern cardiac surgery requires a thorough application of point-of-care (POC) monitoring in order to prevent and readily treat alterations of the haemostatic process. Preoperative platelet dysfunction, residual heparin after extracorporeal circulation, coagulation factors, and/or fibrinogen deficiency could be ruled out and specifically addressed with an appropriate treatment. Our approach includes preoperative platelet function testing of patients administered with thienopyridines or ticagrelor within 7-10 days before planned surgery and platelet function testing-based surgery timing. In the case of postoperative bleeding, residual heparin is tested and additional protamine is eventually administered. Simultaneously, an overall activity of coagulation factors (except fibrinogen) is assessed and, if significantly reduced, correction with prothrombotic complex concentrate is considered. If fibrinogen deficiency is suspected, a specific test is run, and in the case of severe reduction, the deficiency is compensated by fibrinogen concentrate or appropriate volume of fresh-frozen plasma. If both coagulation factors and fibrinogen activity are reduced, fibrinogen is usually considered for correction as first line, followed by prothrombin complex concentrate in the case of further bleeding. It is our clinical practice not to test nor to treat patients until postoperative bleeding appears clinically relevant. At IRCCS Policlinico San Donato, we firmly believe in the importance of the POC-based strategy for haemostatic treatment and constantly update our knowledge through research projects targeted in answering clinically relevant questions.
现代心脏手术围手术期和术后出血的合理管理需要全面应用床旁(POC)监测,以预防和及时治疗止血过程的改变。术前血小板功能障碍、体外循环后残留肝素、凝血因子和/或纤维蛋白原缺乏可以排除,并通过适当的治疗进行针对性处理。我们的方法包括对计划手术前7 - 10天内服用噻吩吡啶类或替格瑞洛的患者进行术前血小板功能测试,以及基于血小板功能测试的手术时机选择。对于术后出血,检测残留肝素,并最终给予额外的鱼精蛋白。同时,评估凝血因子(纤维蛋白原除外)的整体活性,如果显著降低,则考虑用促凝血复合物浓缩物进行纠正。如果怀疑纤维蛋白原缺乏,则进行特定检测,严重降低时,用纤维蛋白原浓缩物或适量新鲜冰冻血浆补充缺乏。如果凝血因子和纤维蛋白原活性均降低,通常首先考虑纠正纤维蛋白原,如进一步出血则给予凝血酶原复合物浓缩物。我们的临床实践是,在术后出血出现临床相关性之前,不对患者进行检测和治疗。在IRCCS圣多纳托综合医院,我们坚信基于床旁检测的止血治疗策略的重要性,并通过旨在回答临床相关问题的研究项目不断更新我们的知识。